Tubulis is a Munich-based biotechnology company engineering uniquely matched antibody-drug conjugates with enhanced biophysical properties for improved on-tumor delivery and wider therapeutic windows. Its proprietary Tubutecan and other ADC platform technologies underpin a growing pipeline designed for high-need solid tumor indications. The lead program, TUB-040 targeting NaPi2b, has shown early clinical proof-of-concept in platinum-resistant high-grade serous ovarian cancer, demonstrating anti-tumor activity at low doses with favorable safety. A second clinical-stage candidate, TUB-030, targets 5T4, and several additional ADCs remain in preclinical development. Proceeds from the company’s latest financing will fund pivotal trials of TUB-040, evaluations in earlier-line ovarian cancer, combination regimens and broader solid tumor exploration. The capital will also advance TUB-030 and preclinical assets while driving further innovation of Tubulis’ ADC technologies for internal programs and partnerships. To date, the firm has secured €344 million (US $401 million) in Series C funding from a global syndicate of life-science investors.

Total raised

$573M

Funding rounds

4

Latest round

Series C

Latest activity

Oct 2025